Home >
Medicine Info >
Volga R 1 mg/0.3 mg Tablet
Loading interface...

Volga R 1 mg/0.3 mg Tablet

Manufactured byAJANTA PHARMA LTD
ContainsRepaglinide (1 mg) + Voglibose (0.3 mg)
Description
Volga R 1 mg/0.3 mg Tablet is a combination medicine used for the treatment of type 2 diabetes mellitus. Patients are advised to maintain a strict exercise and diet regimen along with this medicine to get the best possible effect. This medicine is not recommended for use in patients below 18 years of age.
QUICK LINKS:
Side effectsConcernsUsageRelated products

Side effects

Major & minor side effects for Volga R 1 mg/0.3 mg Tablet

  • Anxiety
  • Blurred vision
  • Chills
  • Confusion
  • Nausea or vomiting
  • Headache
  • Bloody or cloudy urine
  • Flatulence
  • Dizziness
  • Diarrhea

Uses of Volga R 1 mg/0.3 mg Tablet

What is it prescribed for?

  • Type II Diabetes Mellitus
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The effect of this medicine can be observed within 15 to 60 minutes of administration of the dose.
  • How long do the effects of this medicine last?
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Is it safe to consume alcohol while taking this medicine?
    Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
  • Is this a habit forming medicine?
    No habit-forming tendency has been reported.
  • Can this medicine be taken during pregnancy?
    This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
  • Can this medicine be taken while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.

Allergy

This medicine is not recommended for use in patients with a known allergy to repaglinide, voglibose or any other inactive ingredients present along with the formulation.

Diabetic ketoacidosis

This medicine is not recommended for use in patients with diabetic ketoacidosis due to the increased risk of worsening of the patient's condition.

Type 1 Diabetes mellitus

This medicine is not recommended for use in patients with type 1 diabetes mellitus.

Intestinal Obstruction

This medicine is not recommended for use in patients with intestinal obstruction since it may worsen the patient's condition.

Metabolic Acidosis

This medicine is not recommended for use in patients with metabolic acidosis since it may worsen the patient's condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before taking this medicine. Your doctor may prescribe a safer alternative based on your clinical condition.
General warnings

Use in children

This medicine is not recommended for use in children and adolescents since the safety and efficacy of use are not clinically established.

Hypoglycemia

This medicine should be used with extreme caution due to the increased risk of sudden hypoglycemia (low blood sugar levels). Close monitoring of blood glucose levels is recommended during treatment with this medicine. Report any symptoms such as drowsiness, weakness, dizziness, lightheadedness, etc. to the doctor immediately. Appropriate dose adjustments may be required based on the clinical condition.

Gastrointestinal diseases

This medicine is not recommended for use in patients with any gastrointestinal diseases like inflammatory bowel disease, colonic ulceration, partial intestinal obstruction, or any chronic intestinal disease. It is advised that you should inform the doctor about all your medical conditions before beginning treatment with this medicine.

Driving or operating machines

This medicine may cause drowsiness or dizziness in some patients. It is advised that you do not perform any activities that require high mental alertness like driving a vehicle or operating heavy machinery during treatment with this medicine if you experience any of these symptoms.

Liver diseases

This medicine should be used with caution in patients with liver diseases due to the increased risk of worsening of the patient's condition. Close monitoring of the liver function, appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Kidney diseases

This medicine should be used with caution in patients with kidney diseases due to the increased risk of worsening of the patient's condition. Close monitoring of the kidney function, appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Missed Dose

Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Consumption of alcohol is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
Interaction with Medicine

Insulin

Clopidogrel

Gatifloxacin

Cyclosporine

Gemfibrozil

Aspirin

Disease interactions

Cardiovascular disorders

This medicine is not recommended for use in patients with cardiovascular disorders due to the increased risk of death. Replacement with a suitable alternative should be done based on the clinical condition.

Renal Dysfunction

This medicine should be administered with extreme caution in patients suffering from kidney diseases due to the increased risk of worsening of the patient's condition. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.

Hepatic impairment

This medicine should be administered with extreme caution in patients suffering from liver diseases due to the increased risk of worsening of the patient's condition. Appropriate dose adjustments or replacement with a suitable alternative may be required based on the clinical condition.
Food interactions
Consumption of grapefruit juice is not recommended during treatment with this medicine due to the increased risk of severe adverse effects.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take this medicine as prescribed by the doctor. It is advised to take this medicine just before meals or with meals. Regular monitoring of blood sugar levels is recommended during treatment with this medicine. You should always carry a sugar candy with you to counteract unexpected lowering of blood sugar levels. This medicine will show better results if you maintain a strict exercise and diet regimen. Consult the doctor if you experience any undesirable side effects. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

To be taken before food

To be taken as instructed by doctor

May cause sleepiness

How it works
Repaglinide stimulates the pancreas to secrete more insulin; this helps in reducing the blood glucose levels. Voglibose blocks the production of glucose. Their combination is thus effective in reducing blood glucose levels.
Legal Status

Unknown

Unknown

Unknown

Unknown

Classification

Category

Meglitinides, Alpha-glucosidase inhibitors, Oral anti-diabetic combinations

Schedule

Schedule H

DailyMed - Repaglinide tablet [Internet]. Dailymed.nlm.nih.gov. 2017 [cited 23 August 2017]. Available from:

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68064989-47ea-4ed5-a20e-43c4ef6ec271

Repaglinide - DrugBank [Internet]. Drugbank.ca. 2017 [cited 23 August 2017]. Available from:

https://www.drugbank.ca/drugs/DB00912

Repaglinide: MedlinePlus Drug Information [Internet]. Medlineplus.gov. 2017 [cited 23 August 2017]. Available from:

https://medlineplus.gov/druginfo/meds/a600010.html

Voglibose | C10H21NO7 - PubChem [Internet]. Pubchem.ncbi.nlm.nih.gov. 2017 [cited 7 March 2017]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/444020
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 14 Jun 2019

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.